市场调查报告书
商品编码
1353109
全球大肠直肠癌筛检市场规模、份额、行业趋势分析报告:按类型、最终用户、地区分類的展望和预测,2023-2030年Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based), By End-user, By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,大肠直肠癌筛检市场规模预计将达到 222 亿美元,预测期内年复合成长率为 4.8%。
根据 KBV 基数矩阵中的分析,Siemens Hertinius AG 是市场先驱。 2021年4月,西门子收购瓦里安医疗系统,增强了西门子医疗的竞争力与独立性。FUJIFILM Holdings公司、奥林巴斯公司和生物梅里埃公司等公司是市场上的主要创新者。
COVID-19 影响分析
由于COVID-19的影响,疫情期间市场成长放缓。大流行时期的封锁限制和肠癌筛检的取消导致了这一点。 2020 年,许多国家完全停止了内视镜筛检,以减少人与人之间的接触,并为接触 COVID-19 的人节省医院和医疗资源。疫情期间,市场销售成长放缓。在大流行期间,政府计划减少了接受检测的人数。
市场成长要素
大肠直肠癌的风险增加
全球大肠直肠癌罹患率的显着增加是积极影响市场扩张的关键要素之一。由于不健康的生活方式选择和人口爆炸性高龄化,已开发国家的罹患率最高,低收入和中等收入国家的发病率不断上升。此外,根据美国癌症协会的数据,2020年美国将确诊43,340例直肠癌新病例和104,610例结肠癌新病例。大肠直肠癌罹患率的上升和死亡率的上升增加了大肠直肠癌检测的需求,这可能成为未来几年及以后市场扩张的驱动力。
政府癌症筛检政策
一些国家的政府加强了筛检政策,以降低全球大肠癌的发生率。一些国家的政府已经实施了各种配合措施来减轻大肠癌日益增加的负担,包括对罹患族群进行定期筛检。根据美国国家医学图书馆 2019 年发布的一项研究,在韩国,国家癌症筛检计画向所有 50 岁及以上的成年人提供免费或低成本的 CRC 筛检。由于老年人口的增加和政府的配合措施,各种测试的使用预计会增加,从而推动整体市场的扩张。
市场抑制因素
内视镜的不良反应可能导致引入此测试的减少
儘管对先进和高效的筛选测试的需求不断增长,但筛选测试设备的采用可能因其固有的限製而受到阻碍。例如,内视镜的阳性率最高,也是最准确的检查。然而,患者在内视镜过程中可能会出现一些副作用,例如出血和感染。与大肠癌筛检技术相关的这些限制和不利影响预计将在预测期内限制市场扩张。
按类型分類的展望
依类型分为粪便检验、内视镜等。到 2022 年,基于航班的细分市场将在市场中占据重要的收入份额。使用粪便检测诊断结直肠癌和癌前病变已显示出有希望的结果,并已成为早期检测的有用工具。一种创新的基于粪便的测试分析粪便样本,以寻找与大肠癌相关的特定 DNA 标记。政府大肠直肠癌筛检计画的增加和粪便检测效率的提高正在促进这一领域的成长。
飞行型的前景
在粪便检测领域,市场进一步分为粪便免疫化学检查(FIT)、大便潜血试验(FOBT)和粪便DNA检测。粪便免疫化学检查(FIT) 领域在 2022 年占据市场最大的收入份额。 FIT(粪便免疫化学检查)是一种非侵入性诊断程序,用于鉴定粪便中的血液。 FIT被广泛用作诊断工具,透过检测粪便样本中的血液来检测癌前病变和早期大肠癌。 FIT 的发展重点是提高敏感性、特异性和患者友善性。
最终用户前景
根据最终用户,市场分为医院和诊所、临床实验室、影像影像中心等。 2022年,医院和诊所细分市场以最大的收入份额主导市场。该细分市场的成长归因于大肠直肠癌患病的上升以及全球医院筛检测试的技术进步。由于医院数量众多等因素,医院和诊所对大肠癌筛检的需求不断增加。
区域展望
从区域来看,我们对北美、欧洲、亚太地区和拉丁美洲地区的市场进行了分析。 2022年,亚太地区在市场中获得了显着的收入份额。亚洲国家的市场开拓和医疗设施升级、该地区国家大肠癌罹患率的上升以及个人对更好治疗结果的认识不断提高,推动了该区域市场的扩张。此外,该地区主要国家结直肠癌罹患率的上升以及大肠直肠疾病成为主要死亡原因预计也将推动该地区的市场成长。
The Global Colorectal Cancer Screening Market size is expected to reach $22.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.
In United States, approximately nine out of ten people with colorectal cancer who are diagnosed early and treated appropriately are still alive five years later. Hence, the North America region would capture approximately 2/5th of the market by 2030. Due to several factors, including an aging population, an increase in cancer cases, high healthcare spending, and a modern healthcare infrastructure. The market is also expanding due to rising government initiatives to create awareness of the disease and the accessibility of screening tests like FIT and FOBT.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In April, 2022, BioMerieux S.A. acquired Specific Diagnostics to enhances bioMerieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio. In December, 2022, Olympus Corporation took over Odin Vision to reinforce Olympus' strategy for delivering digital patient care.
Based on the Analysis presented in the KBV Cardinal matrix; Siemens Healthineers AG is the forerunner in the Market. April, 2021, Siemens took over Varian Medical Systems to strengthen the competitiveness & independence of Siemens Healthineers. Companies such as Fujifilm Holdings Corporation, Olympus Corporation, BioMerieux S.A. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 effect caused the market growth to slow down during the pandemic. Pandemic-era lockdown limitations and a suspension of colorectal cancer screening brought this on. To decrease person-to-person contact and conserve hospital and medical resources for those exposed to COVID-19, screening through colonoscopies was completely discontinued in many countries in 2020. The market slowed in growth during the pandemic period when measured by revenue. During the pandemic, there was a decrease in the number of people being examined through government programs.
Market Growth Factors
Growing Risk of Colorectal Cancer
The substantial rise in global colorectal cancer incidence is one of the key factors that favorably influence the market's expansion. The incidence is highest in developed nations, rising in middle- and low-income nations because of unhealthy lifestyle choices and an aging population explosion. Additionally, according to the American Cancer Society, 43,340 new instances of rectal cancer and 104,610 new cases of colon cancer were identified in the United States in 2020, respectively. The demand for CRC detection has increased due to the rising incidence of CRC and the disease's rising death rate, which will likely drive the expansion of the market in the following years.
Government Cancer Screening Policies
Governments in several nations have strengthened screening policies to reduce the incidence of colorectal cancer on a global scale. Governments in several nations have implemented various initiatives, such as regular screening programs for individuals at risk of contracting the disease, to reduce the growing burden of CRC. In Korea, the National Cancer Screening Program offers CRC screening to all adults over 50 at no or at a low cost, according to a study released by the National Library of Medicine in 2019. The usage of various tests is anticipated to increase due to the growing elderly population and government initiatives, which will fuel market expansion overall.
Market Restraining Factors
Negative Effects of Colonoscopies May Lead to Decreased Adoption of Testing
Despite the critical and growing need for advanced and efficient screening procedures, adopting screening devices may be hampered by their inherent limitations. A colonoscopy, for instance, has the highest incidence of positive results and is a highly accurate test. However, the patient may experience several negative side effects from the colonoscopy process, including bleeding and infection. During the forecast period, these restrictions and unfavorable effects related to colorectal cancer screening techniques are anticipated to restrain market expansion.
Type Outlook
By type, the market is segmented into stool-based, colonoscopy, and others. The stool-based segment covered a considerable revenue share in the market in 2022. The diagnosis of colorectal cancer and precancerous lesions using stool-based tests has shown encouraging results, making it a useful tool for early detection. The revolutionary stool-based tests analyze stool samples to find specific DNA markers related to colorectal cancer. Increased government programs for colorectal cancer screening and the efficiency of stool-based tests have contributed to the segment's growth.
Stool-based type Outlook
Under the stool-based segment, the market is further divided into fecal immunochemical test (FIT), fecal occult blood test (FOBT), and stool-DNA test. The fecal immunochemical test (FIT) segment witnessed the largest revenue share in the market in 2022. The FIT, or fecal immunochemical test, is a non-invasive diagnostic procedure used to identify blood in stool. FITs are extensively utilized diagnostic tools for detecting precancerous lesions or early-stage colorectal cancer by detecting blood in stool samples. The development of FITs has focused on enhancing their sensitivity, specificity, and patient friendliness.
End-user Outlook
Based on end-user, the market is bifurcated into hospital & clinics, clinical laboratories, diagnostic imaging centers, and others. In 2022, the hospitals and clinics segment dominated the market with maximum revenue share. The growth of the segment is attributable to the rise in the prevalence of colorectal cancer and technological advancements in screening tests conducted in hospitals globally. The demand for CRC screening is expanding in hospitals and clinics due to elements including a sizable number of hospitals.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. The expansion of the regional market is driven by the development and upgrading of healthcare facilities in Asian nations, rising CRC incidence in the region's nations, and rising individual consciousness of better treatment outcomes. It is expected that the rising incidence of colorectal cancer in the region's key countries and the status of colorectal diseases as the primary cause of mortality will also drive market growth in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG)
Strategies deployed in Colorectal Cancer Screening Market
Jul-2023: BioMerieux S.A. signed a partnership with Oxford Nanopore, a medical technology company, to provide nanopore sequencing solutions within the infectious disease diagnostics market. The partnership provides BioMerieux with opportunities for exploring new technologies for improved patient care.
Dec-2022: Olympus Corporation took over Odin Vision, an endoscopy solutions provider. The acquisition reinforces Olympus' strategy for delivering digital patient care.
Apr-2022: BioMerieux S.A. acquired Specific Diagnostics, an antimicrobial susceptibility test (AST) specialist. The acquisition enhances bioMerieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio.
May-2021: Fujifilm Holdings Corporation signed a partnership with Helio Health, an AI-powered healthcare solutions provider, to develop solutions for early detection of liver cancer. The partnership would provide clinicians around the world with market-leading diagnostic and surveillance technologies.
Apr-2021: Siemens took over Varian Medical Systems, a U.S. company active in the region of cancer research & therapy. This acquisition would allow Siemens to strengthen the competitiveness & independence of Siemens Healthineers. The acquisition further focused on creating a world-leading company in cancer therapy.
Jan-2021: Fujifilm Holdings Corporation expanded its geographical footprint by opening a new centre named "NURA" in Bangalore, India. The centre would serve as a medical screening service business for the company.
Market Segments covered in the Report:
By Type
By End-user
By Geography
Companies Profiled
Unique Offerings from KBV Research